HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplements Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Bakkar, A. A. Articles by Grandchamp, B. Search for Related Content PubMed PubMed Citation Articles by Bakkar, A. A. Articles by Grandchamp, B. Related Collections Molecular Diagnostics and Genetics

Sensitive Allele-Specific PCR Assay Able to Detect FGFR3 Mutations in Tumors and Urine from Patients with Urothelial Cell Carcinoma of the Bladder

¹ EMI INSERM 03-37 and Service d’Urologie, Université Paris 12, AP-HP, Hôpital Henri Mondor, Créteil, France;
² Service de Biochimie et Génétique,³ Service d’Anatomie et Cytologie Pathologiques, and⁶ Service d’Urologie, Université Paris 7, AP-HP, IFR02, Hôpital Bichat-Claude Bernard, Paris, France;
⁴ UMR 144, CNRS Institut Curie, Paris, France;
⁵ Service d’Urologie CHRU Besançon, France;

^aaddress correspondence to this author at: Service de Biochimie et Génétique, Hôpital Bichat, 46 rue Henri Huchard 75018 Paris, France

The first 300 words of the full text of this article appear below.

Activating somatic point mutations in exons 7, 10, and 15 of the FGFR3 gene are frequently observed in urothelial cell carcinoma (UCC) (1)(2). These mutations have been found primarily in superficial papillary pTa tumors and were absent in carcinoma in situ (3).

Given the high frequency of FGFR3 mutations and the possible implication of this receptor in the development of UCC, it was important to develop a simple, fast, and reliable method to identify these mutations in greater detail as a potential tool for the diagnosis and follow-up of UCC patients.

Ten different FGFR3 mutations have been described in UCC, but 4 of them (R248C, S249C, G372C, and Y375C) account for >95% of cases (2). These mutations therefore represent an excellent target for assays, such as allele-specific PCR (AS-PCR), that depend on the specific detection of point mutations.

The general principle underlying the AS-PCR technique is to design a mutation-specific primer that produces the preferential amplification of a specific mutant allele (4). We compared the results obtained with this assay with those obtained by direct sequencing in a series of 95 DNA samples extracted from UCC tumors. We also analyzed matching tumors and voided urine from 20 patients. Our results demonstrate the sensitivity, specificity, and reliability of this technique for detecting FGFR3 mutations in both tumors and urine from patients with UCC.

Ninety-five primary tumor samples were collected from patients admitted to the Department of Urology of Hospitals Henri Mondor (Creteil) and CHRU (Besancon) and who had received no previous treatment. Patients gave written informed consent, and we collected matched tumors and blood samples. Tumors from each patient were snap-frozen and stored at –80 °C. DNA from tumor samples was extracted as described previously (5). DNA was extracted . . . [Full Text of this Article]